Loading
Latest filing published 16 Mar 2026 for Ultralife CORP, €9,372.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Michael Edward Manna on record concern Ultralife Corp. Over a trading history stretching from 12 December 2022 to 12 March 2026, the count stands at 17 filings.
The open-market record is one-sided, with 14 purchases worth €100k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 2 option exercises. Since January 2026: 2 purchases and no sales on the market.
The median purchase comes to €6,089. On 8 out of 14 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. For 6 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +14.0%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 16 March 2026: an open-market purchase of €1,045, in Ultralife Corp. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations